A phase IIIb, open, multi-country, controlled, randomized study to demonstrate the immunogenicity and safety of GSK Biological meningococcal conjugate vaccine, MenACWYTT (GSK134612) in healthy infants, given on a 3+1 primary and booster (2, 4, 6 and 15-18 months of age), a 1+1 primary and booster (6 and 15-18 months of age), or as a single dose at 15-18 months of age
2022-06-28
عنوان الدراسة
A phase IIIb, open, multi-country, controlled, randomized study to demonstrate the immunogenicity and safety of GSK Biological meningococcal conjugate vaccine, MenACWYTT (GSK134612) in healthy infants, given on a 3+1 primary and booster (2, 4, 6 and 15-18 months of age), a 1+1 primary and booster (6 and 15-18 months of age), or as a single dose at 15-18 months of age
داعم الدراسة
GSK
دواء الدراسة
Infanrix-IPV/HiberixTM/SynflorixTM/GSK 134612
رقم بروتوكول الدراسة
114858
حالة الدراسة
Rejected
موقع الدراسة
KFMC
مرحلة الدراسة
3b
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。